CLINICAL PHENOMENA IN SCHIZOPHRENIA AND DEVELOPMENT OF NOVEL TREATMENTS

尽管在临床表现上有很大的不同 精神分裂症，临床医生仍然很难设计出新的 治疗Z01MH02395或预测易受负面结果影响 (包括药物副作用)根据体征和症状 失调症的症状。通过聚焦于某些临床特征， 针对精神分裂症，我们设计了一系列实验性的 药物治疗Z01MH02395。这涉及到这样一个概念，即 障碍与认知能力受损有关。 因此，我们已经开始了可能会改善的药物试验 认知力。我们的第一个这样的试验使用了DDAVP，至少 适度的成功。我们正在完成一项 水剂，另一种与改善疗效有关的药物 认知力。

Despite wide variations in the clinical manifestations of schizophrenia, it remains difficult for clinicians to design novel treatZ01MH02395 or predict vulnerability to negative outcomes (including medication side effects) based on signs and symptoms of the disorder. By focusing on certain clinical characteristics of schizophrenia, we have designed a series of experimental medication treatZ01MH02395. This involves the notion that the disorders is associated with impairment cognitive performance. Hence, we have begun trails of medication that may improve cognition. Our first such trail utilized DDAVP with at least modest success. We are in the process of completing a trail of hydrergine, another medication associated with improved cognition.